TW200610754A - Vla-4 inhibitor - Google Patents
Vla-4 inhibitorInfo
- Publication number
- TW200610754A TW200610754A TW094118992A TW94118992A TW200610754A TW 200610754 A TW200610754 A TW 200610754A TW 094118992 A TW094118992 A TW 094118992A TW 94118992 A TW94118992 A TW 94118992A TW 200610754 A TW200610754 A TW 200610754A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- salt
- aryl group
- producing
- vla
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004175094 | 2004-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200610754A true TW200610754A (en) | 2006-04-01 |
Family
ID=35503004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW094118992A TW200610754A (en) | 2004-06-14 | 2005-06-09 | Vla-4 inhibitor |
Country Status (5)
Country | Link |
---|---|
US (1) | US20070232601A1 (zh) |
EP (1) | EP1757602A1 (zh) |
JP (1) | JPWO2005121135A1 (zh) |
TW (1) | TW200610754A (zh) |
WO (1) | WO2005121135A1 (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5107724B2 (ja) | 2005-12-13 | 2012-12-26 | 第一三共株式会社 | Vla−4阻害薬 |
WO2008103378A2 (en) | 2007-02-20 | 2008-08-28 | Merrimack Pharmaceuticals, Inc. | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
PL2288715T3 (pl) | 2008-04-11 | 2015-03-31 | Merrimack Pharmaceuticals Inc | Łączniki będące albuminą surowicy ludzkiej i ich koniugaty |
BRPI0921586A2 (pt) | 2008-11-18 | 2019-09-24 | Merrimack Pharmaceuticals Inc | articuladores de albumina de soro humana e conjugados destes |
US9345766B2 (en) | 2012-08-30 | 2016-05-24 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-ERBB3 agents |
CA3114240C (en) | 2018-10-30 | 2023-09-05 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
CA3115830C (en) | 2018-10-30 | 2023-09-12 | Gilead Sciences, Inc. | Compounds for inhibition of .alpha.4.beta.7 integrin |
AU2019373240B2 (en) | 2018-10-30 | 2023-04-20 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
US11224600B2 (en) | 2018-10-30 | 2022-01-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
WO2021030438A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1415099A (en) * | 1997-11-18 | 1999-06-07 | Merck & Co., Inc. | 4-substituted-4-piperidine carboxamide derivatives |
EP1049665A1 (en) * | 1998-01-23 | 2000-11-08 | Novartis AG (Novartis SA) (Novartis Inc.) | Vla-4 antagonists |
SK20052000A3 (sk) * | 1998-06-30 | 2002-08-06 | Pfizer Products Inc. | Nepeptidové inhibítory VLA-4 dependentnej bunkovej väzby použiteľné pri liečení zápalových, autoimunitných a respiračných chorôb |
GB9916374D0 (en) * | 1998-07-23 | 1999-09-15 | Zeneca Ltd | Chemical compounds |
PL357109A1 (en) * | 1999-12-28 | 2004-07-12 | Pfizer Products Inc. | Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
RU2290403C2 (ru) * | 2000-12-28 | 2006-12-27 | Дайити Фармасьютикал Ко., Лтд. | Ингибиторы vla-4 |
-
2005
- 2005-06-09 TW TW094118992A patent/TW200610754A/zh unknown
- 2005-06-14 EP EP05751029A patent/EP1757602A1/en not_active Withdrawn
- 2005-06-14 US US11/629,354 patent/US20070232601A1/en not_active Abandoned
- 2005-06-14 WO PCT/JP2005/010894 patent/WO2005121135A1/ja not_active Application Discontinuation
- 2005-06-14 JP JP2006514610A patent/JPWO2005121135A1/ja not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20070232601A1 (en) | 2007-10-04 |
EP1757602A1 (en) | 2007-02-28 |
WO2005121135A1 (ja) | 2005-12-22 |
JPWO2005121135A1 (ja) | 2008-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200610754A (en) | Vla-4 inhibitor | |
TW200628154A (en) | Organic compounds | |
IL201253A0 (en) | A transition metal catalyzed synthesis of n - aminoindoles | |
WO2005097788A3 (en) | Sulfonamides and uses thereof | |
NZ627250A (en) | Novel nicotinamide derivative or salt thereof | |
WO2008108380A3 (en) | Pyrrole compounds | |
WO2009068531A3 (en) | Adamantyl o-glucuronide derivatives as inhibitors of dipeptidyl peptidase iv for the treatment of diabetes | |
TW200732339A (en) | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | |
WO2005113515A8 (de) | Pyrimidine als plk inhibitoren | |
WO2007045462A3 (de) | Neue vanilloid-rezeptor liganden und ihre verwendung zur herstellung von arzneimitteln | |
WO2006112549A8 (ja) | 縮合複素環化合物 | |
MY150379A (en) | Fused heterocyclic derivative and use thereof | |
MY149070A (en) | 1h-quinazoline-2,4-diones | |
WO2008153947A3 (en) | Heterocyclic compounds as raf kinase modulators | |
TW200617009A (en) | Organic compounds | |
CR7680A (es) | Un nuevo proceso para la sintesis de agomelatina | |
WO2009000441A8 (en) | Processes for the preparation of pyrazoles | |
TW200732335A (en) | Organic compounds | |
MX2009014203A (es) | Una sintesis de 2h-indazoles catalizada por un metal de transicion. | |
DE502005010342D1 (en) | Substituierte cyclohexylessigsäure-derivate | |
WO2008001195A3 (en) | Novel processes for the preparation of dpp iv inhibitors | |
WO2008125337A3 (de) | Neue vanilloid-rezeptor liganden und ihre verwendung zur herstellung von arzneimitteln | |
MX2010005649A (es) | Compuestos novedosos como ligandos del receptor canabinoide y sus usos. | |
WO2007065684A3 (en) | Bicyclic heteroyclic compounds as antiinflammatory or antiallergic agents | |
MX2008012332A (es) | Tiazolil-dihidro-indazoles. |